CHMP turns down new indication for Lilly's duloxetine, again
This article was originally published in Scrip
Executive Summary
Lilly would have to submit a whole new application to the European Medicines Agency if it wanted to secure a new indication for three of its duloxetine products for treating moderate to severe chronic somatic pain in patients who do not regularly take NSAIDs.